Slide 1: Interim report Q3 / 2022
Interim report Q3 / 2022 2022-10-27 Vitrolife AB (publ) Thomas Axelsson, CEO Patrik Tolf, CFO
Slide 2: Actions done and synergies ahead
Actions done and synergies ahead Third quarter Sales Growth Pro forma excluding Covid-19 Gross margin 798 MSEK +5% 53.6% +97% in SEK In local currencies (56.4 % Pro forma) EBITDA EBITDA per share Operating cash flow 276 MSEK 2.04 SEK 200 MSEK Margin 34.5% (33.9% Pro forma) +47% +87% in SEK YTD Sales
Slide 3: Sales and growth per market region
Sales and growth per market region Total Q3 growth rate (local currencies) 222% 33% 33% 88% 76% Organic growth* (local currencies) 7% -8% 10% 32% 5% Sales (MSEK) 300 256 137 105 798 Share of Vitrolife 38% 32% 17% 13% Group’s sales * pro forma excluding Covid-19 tests 3
Slide 4: Consumables business area
Consumables business area 18% 348 334 6% In local currencies 307 280 284 286 254 243 4% -9% Americas EMEA 27% 18% Asia Japan Pacific Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 2022 Net sales MSEK 4
Slide 5: Technologies business area
Technologies business area -5% 141 136 140 -9% In local currencies 129 122 114 116 102 -31% -30% Americas EMEA -21% 99% Asia Japan Pacific Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 2022 Net sales MSEK 5
Slide 6: Genetic Services* business area
Genetic Services* business area 25% 346 337 9% in local currencies 296 293 278 274 257 246 11% 12% Americas EMEA -3% 1% Asia Japan Pacific Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 2022 Net sales MSEK 6 *Genetic Services excluding business related to Covid-19 tests
Slide 7: Q3 financial highlights
Q3 financial highlights Net sales of SEK 798 million (406), + 97% 798 • Sales growth offset decline in sales for Covid-19 testing MSEK • Positive impact from currencies of SEK 81 million 713 • 5% growth in local currencies (pro forma excluding Covid-19 testing). 307 Gross income of SEK 428 million (
Slide 8: Operating expenses
Operating expenses +8% MSEK 274 254 • Normalised business activities 132 • Negative exchange rate impact 19 MSEK • Reduced running costs 274 122 21Q3 22Q3 Pro forma Genetic Services Vitrolife 8
Slide 9: Key financials and pro forma
Key financials and pro forma 2022 2021 2021 Q3 Pro 2021 Delta Pro forma 2022 Q1-Q3 Q3 Q3 forma Q1-Q3 Sales, MSEK 798 406 713 +85 2,379 1,167 Gross Margin, % 54% 65% 56% -2ppt 55% 64% Adj. Gross Margin, %* 56% 65% 59% -3ppt 58% 65% Adjusted EBITDA, MSEK** 276 170 242 +34 777 482 Adjusted EBITDA, %**
Slide 10: Management comments
Management comments Synergies from customer interactions and development One global S&M organisation Restructured Genetic Services 10
Slide 11: Q/A Session
Q/A Session Contact: Thomas Axelsson, CEO, taxelsson@vitrolife.com, +46 31 721 80 01 Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21
Slide 12: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i